Evaluation of a microarray-based genotyping assay for the rapid detection of cytochrome P450 2C19 *2 and *3 polymorphisms from whole blood using nanoparticle probes

American Journal of Clinical Pathology

Volumn 136, Issue 4, 2011, Pages 604-608

  Buchan, Blake W ^a,b   Peterson, Jess F ^a   Cogbill, Christopher H ^a   Anderson, Dennis K ^c   Ledford, Joellen S ^c   White, Mary N ^c   Quigley, Neil B ^c   Jannetto, Paul J ^a,b   Ledeboer, Nathan A ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b DYNACARE LABORATORIES   (Canada)

^c Molecular Pathology Laboratory Network Inc   (United States)

Author keywords

CYP2C19; Molecular detection assay; Nanoparticle; Polymorphism

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; DRUG METABOLITE; NANOPARTICLE;

ARTICLE; BLOOD SAMPLING; DNA POLYMORPHISM; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; REPRODUCIBILITY;

ARYL HYDROCARBON HYDROXYLASES; GENOTYPE; HEMATOLOGIC TESTS; HUMANS; NANOSPHERES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TICLOPIDINE; TIME FACTORS;

EID: 80053464779     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPCPU9Q2IRNYXC     Document Type: Article

References (21)

1. Kujovich JL. Factor V Leiden thrombophilia. Genet Med. 2011;13:1-16.
2. Schwann TA, Kistler L, Engoren MC, et al. Incidence and predictors of postoperative deep vein thrombosis in cardiac surgery in the era of aggressive thromboprophylaxis. Ann Thorac Surg. 2010;90:760-766.
3. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 suppl):630S-669S. (Pubitemid 351892974)
4. Bonaca MP, Steg PG, Feldman LJ, et al. Antithrombotics in acute coronary syndromes. J Am Coll Cardiol. 2009;54:969-984.
5. Li X, Quigg RJ, Zhou J, et al. Clinical utility of microarrays: current status, existing challenges and future outlook. Curr Genomics. 2008;9:466-474.
6. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391-396. (Pubitemid 47219454)
7. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92-99.
8. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505-1516. (Pubitemid 46517957)
9. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010;56:134-143.
10. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.cypalleles.ki.se. Last updated September 9, 2008. Accessed March 2010.
11. De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594-598. (Pubitemid 24334747)
12. De Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269:15419-15422.
13. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815-850. (Pubitemid 32385908)
14. Gurbel PA, Tantry US, Shuldiner AR, et al. Genotyping: one piece of the puzzle to personalize antiplatelet therapy. J Am Coll Cardiol. 2010;56:112-116.
15. Jin B, Ni H-C, Shen W, et al. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel [published online ahead of print September 16, 2010]. Mol Biol Rep. 2011;38:1697-1702. doi:10.1007/s11033-010-0282-0.
16. Bonello L, Armero S, Ait Mokhtar O, et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol. 2010;56:1630-1636.
17. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849-857.
18. Storhoff JJ, Marla SS, Bao P, et al. Gold nanoparticle-based detection of genomic DNA targets on microarrays using a novel optical detection system. Biosens Bioelectron. 2004;19:875-883. (Pubitemid 38201338)
19. Jannetto PJ, Buchan BW, Vaughan KA, et al. Real-time detection of influenza A, influenza B, and respiratory syncytial virus A and B in respiratory specimens by use of nanoparticle probes. J Clin Microbiol. 2010;48:3997-4002.
20. Calatzis A, Leitner M, Panzer S. Monitoring anticoagulation of primary haemostasis: estimation of platelet function in whole blood assays. Hamostaseologie. 2009;29:279-284.
21. Heller T, Kirchheiner J, Armstrong VW, et al. AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit. 2006;28:673-677. (Pubitemid 44564068)